Warning: The NCBI web site requires JavaScript to function. more...
New targets for therapy in breast cancer: mammalian target of rapamycin (mTOR) antagonists.
Carraway H, Hidalgo M.
Breast Cancer Res. 2004;6(5):219-24. Epub 2004 Aug 12. Review.
Related citations
Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.
deGraffenried LA, Friedrichs WE, Russell DH, Donzis EJ, Middleton AK, Silva JM, Roth RA, Hidalgo M.
Clin Cancer Res. 2004 Dec 1;10(23):8059-67.
Mammalian target of rapamycin: a new molecular target for breast cancer.
Mita MM, Mita A, Rowinsky EK.
Clin Breast Cancer. 2003 Jun;4(2):126-37. Review.
G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells.
Gao N, Flynn DC, Zhang Z, Zhong XS, Walker V, Liu KJ, Shi X, Jiang BH.
Am J Physiol Cell Physiol. 2004 Aug;287(2):C281-91. Epub 2004 Mar 17.
Insulin-like growth factor-I inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway: progesterone receptor as a potential indicator of growth factor activity in breast cancer.
Cui X, Zhang P, Deng W, Oesterreich S, Lu Y, Mills GB, Lee AV.
Mol Endocrinol. 2003 Apr;17(4):575-88. Epub 2003 Jan 2. Erratum in: Mol Endocrinol. 2003 Sep;17(9):1892.
Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade.
Shi Y, Yan H, Frost P, Gera J, Lichtenstein A.
Mol Cancer Ther. 2005 Oct;4(10):1533-40.
Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin module for acute myelogenous leukemia therapy: from bench to bedside.
Martelli AM, Tazzari PL, Evangelisti C, Chiarini F, Blalock WL, Billi AM, Manzoli L, McCubrey JA, Cocco L.
Curr Med Chem. 2007;14(19):2009-23. Review.
Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition.
Sun SY, Rosenberg LM, Wang X, Zhou Z, Yue P, Fu H, Khuri FR.
Cancer Res. 2005 Aug 15;65(16):7052-8.
Signal transduction pathways in androgen-dependent and -independent prostate cancer cell proliferation.
Ghosh PM, Malik SN, Bedolla RG, Wang Y, Mikhailova M, Prihoda TJ, Troyer DA, Kreisberg JI.
Endocr Relat Cancer. 2005 Mar;12(1):119-34.
Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3 kinase/Akt pathway.
DeGraffenried LA, Fulcher L, Friedrichs WE, Grünwald V, Ray RB, Hidalgo M.
Ann Oncol. 2004 Oct;15(10):1510-6.
Targeting the Akt/mammalian target of rapamycin pathway for radiosensitization of breast cancer.
Albert JM, Kim KW, Cao C, Lu B.
Mol Cancer Ther. 2006 May;5(5):1183-9.
Activation of mammalian target of rapamycin in transformed B lymphocytes is nutrient dependent but independent of Akt, mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, insulin growth factor-I, and serum.
Wlodarski P, Kasprzycka M, Liu X, Marzec M, Robertson ES, Slupianek A, Wasik MA.
Cancer Res. 2005 Sep 1;65(17):7800-8.
Thyroid hormone induces rapid activation of Akt/protein kinase B-mammalian target of rapamycin-p70S6K cascade through phosphatidylinositol 3-kinase in human fibroblasts.
Cao X, Kambe F, Moeller LC, Refetoff S, Seo H.
Mol Endocrinol. 2005 Jan;19(1):102-12. Epub 2004 Sep 23.
Synergistic augmentation of rapamycin-induced autophagy in malignant glioma cells by phosphatidylinositol 3-kinase/protein kinase B inhibitors.
Takeuchi H, Kondo Y, Fujiwara K, Kanzawa T, Aoki H, Mills GB, Kondo S.
Cancer Res. 2005 Apr 15;65(8):3336-46.
Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer.
Chan S.
Br J Cancer. 2004 Oct 18;91(8):1420-4. Review.
Current status and challenges associated with targeting mTOR for cancer therapy.
Dowling RJ, Pollak M, Sonenberg N.
BioDrugs. 2009;23(2):77-91. doi: 10.2165/00063030-200923020-00002. Review.
Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy.
Tsurutani J, West KA, Sayyah J, Gills JJ, Dennis PA.
Cancer Res. 2005 Sep 15;65(18):8423-32.
The molecular target of rapamycin (mTOR) as a therapeutic target against cancer.
Cancer Biol Ther. 2003 Jul-Aug;2(4 Suppl 1):S169-77. Review.
Mammalian target of rapamycin is a promising target for novel therapeutic strategy against cancer.
Bjelogrlić SK, Srdić T, Radulović S.
J BUON. 2006 Jul-Sep;11(3):267-76. Review.
Survival signaling by Notch1: mammalian target of rapamycin (mTOR)-dependent inhibition of p53.
Mungamuri SK, Yang X, Thor AD, Somasundaram K.
Cancer Res. 2006 May 1;66(9):4715-24.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on